Journal of Food and Nutrition Research
ISSN (Print): 2333-1119 ISSN (Online): 2333-1240 Website: http://www.sciepub.com/journal/jfnr Editor-in-chief: Prabhat Kumar Mandal
Open Access
Journal Browser
Go
Journal of Food and Nutrition Research. 2016, 4(10), 633-639
DOI: 10.12691/jfnr-4-10-1
Open AccessReview Article

Effects of Chromium Picolinate Supplementation on Control of Metabolic Variables: A Systematic Review

Bruna Marmett1 and Ramiro Barcos Nunes2, 3,

1Laboratory of Air Pollution, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil

2Laboratory of Physiology, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil

3Research Department, Instituto Federal de Educação, Ciência e Tecnologia Sul-rio-grandense, Gravataí, Brazil

Pub. Date: September 14, 2016

Cite this paper:
Bruna Marmett and Ramiro Barcos Nunes. Effects of Chromium Picolinate Supplementation on Control of Metabolic Variables: A Systematic Review. Journal of Food and Nutrition Research. 2016; 4(10):633-639. doi: 10.12691/jfnr-4-10-1

Abstract

Chromium picolinate is widely used as a supplement to improve glucose metabolism, insulin sensitivity and lipid profile. Its actions, however, extend beyond these metabolic changes, as it has positive effects in the clinical setting of cardiovascular disease, shows anti-inflammatory and antioxidant properties, and even modulates behavior patterns, such as in depression and anxiety. In view of the numerous possible applications of chromium picolinate, understanding the therapeutic properties of this supplement becomes necessary. Thus, the aim of this review is clarify and identify the applications of chromium picolinate, as well as its effectiveness under several clinical conditions. A systematic review was performed during July and September of 2015 through a search on PubMed, Web of Knowledge and SciElo databases using the keywords ‘chromium picolinate’ and ‘supplementation’. Articles selected were published between 2005 and 2015 and written in English, Portuguese and Spanish. The search resulted in 361 articles (Web of Knowledge: 245, Pubmed: 115, SciElo: 1) and after inclusion and exclusion criteria was applied, 12 articles were selected to analyze by reading the full text. Articles reviewed demonstrate that chromium picolinate has a positive action in glucose control, oxidative stress, lipid profile, protein synthesis, binge eating disorder and cognitive decline, although some studies showed absence of effect. Also, a difference was observed in dosage of the supplementation among different samples and there was a largely variable time of treatment. Chromium picolinate supplementation appears to positively contribute to the improvement of metabolic control and health, and could potentially be used as an auxiliary therapy in several diseases.

Keywords:
chromium tripicolinate dietary supplement glucose metabolism lipid metabolism oxidative stress behavior control

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  J.B. Vincent, “Elucidating a biological role for chromium at a molecular level”, Accounts of Chemical Research 33(7). 503-510. Jul.2000.
 
[2]  R.A. Anderson, “Chromium and insulin resistance”, Nutrition Research Reviews 16(2). 267-275. Dec. 2003.
 
[3]  Z.Q. Wang, W.T. Cefalu, “Current Concepts About Chromium Supplementation in Type 2 Diabetes and Insulin Resistance”, Current Diabetes Reports 10(2) 145-151. Apr.2010.
 
[4]  M. Peng, X. Yang, “Controlling diabetes by chromium complexes: The role of the ligands”, Journal of Inorganic Biochemistry 146. 97-103. May.2015.
 
[5]  R.I. Press, J. Geller, G.W. Evans, “The effect of chromium picolinate on serum-cholesterol and apolipiprotein fractions in human-subjects”, Western Journal of Medicine 152(1). 41-45. Jan.1990.
 
[6]  N. Suksomboon, N. Poolsup, A. Yuwanakorn, “Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes”, Journal of Clinical Pharmacy and Therapeutics 39(3). 292-306. Jun.2014.
 
[7]  J.S. Volek, R. Silvestre, J.P. Kirwan, M.J. Sharman, D.A. Judelson, B.A. Spiering, J.L. Vingren, C.M. Maresh, J.L. Vanheest, W.J. Kraemer, “Effects of chromium supplementation on glycogen synthesis after high-intensity exercise”, Medicine and Science in Sports and Exercise 38(12). 2102-2109. Dec2006.
 
[8]  W. Abebe, J.Y. Liu, H. Wimborne, M.S. Mozaffari, “Effects of chromium picolinate on vascular reactivity and cardiac ischemia-reperfusion injury in spontaneously hypertensive rats”, Pharmacological Reports 62(4). 674-682. Jul.2010.
 
[9]  N.M. Al-Rasheed, H.A. Attia, R.A. Mohamed, N.M. Al-Rasheed, M. Al-Amin, “Preventive Effects of Selenium Yeast, Chromium Picolinate, Zinc Sulfate and their Combination on Oxidative Stress, Inflammation, Impaired Angiogenesis and Atherogenesis in Myocardial Infarction in Rats”, Journal of Pharmacy and Pharmaceutical Sciences 16(5). 848-867. 2013.
 
[10]  V.K. Dubey, F. Ansari, D. Vohora, R. Khanam, “Possible involvement of corticosterone and serotonin in antidepressant and antianxiety effects of chromium picolinate in chronic unpredictable mild stress induced depression and anxiety in rats”, Journal of Trace Elements in Medicine and Biology 29. 222-226. 2015.
 
[11]  J.B. Vincent, “Recent advances in the nutritional biochemistry of trivalent chromium”, Proceedings of the Nutrition Society 63(1). 41-47. Feb.2004.
 
[12]  W.T. Cefalu, J. Rood, P. Pinsonat, J. Qin, O. Sereda, L. Levitan, R.A. Anderson, X.H. Zhang, J.M. Martin, C.K. Martin, Z.Q. Wang, B. Newcomer, “Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus”, Metabolism-Clinical and Experimental 59(5). 755-762. May.2010.
 
[13]  K.A. Brownley, A. Von Holle, R.M. Hamer, M. La Via, C.M. Bulik, “A double-blind, randomized pilot trial of chromium picolinate for binge eating disorder: Results of the Binge Eating and Chromium (BEACh) Study”, Journal of Psychosomatic Research 75(1). 36-42. 2013.
 
[14]  Z.Q. Wang, X.H. Zhang, J.C. Russell, M. Hulver, W.T. Cefalu, “Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR: LA-cp rats”, Journal of Nutrition 136(2). 415-420. Jul.2006.
 
[15]  H. Ahmad, Z. Ahmed, R. Khan, “Effect of Chromium Picolinate Supplementation on Diabetic Profile and Nutritional Status of the Type-2 Diabetic Adult Population – A Randomized Controlled Trial”, Journal of Food and Nutrition Research, 4(8). 535-542. 2016.
 
[16]  D.J. McIver, A.M. Grizales, J.S. Brownstein, A.B. Goldfine, “Risk of Type 2 Diabetes Is Lower in US Adults Taking Chromium-Containing Supplements”, Journal of Nutrition 145(12). 2675-2682. Dec.2015.
 
[17]  S. Huang, W. Peng, X. Jiang, K. Shao, L. Xia, Y. Tang, J. Qiu, “The Effect of Chromium Picolinate Supplementation on the Pancreas and Macroangiopathy in Type II Diabetes Mellitus Rats”, Journal of Diabetes Research , 2014.
 
[18]  B. Sundaram, A. Aggarwal, R. Sandhir, “Chromium picolinate attenuates hyperglycemia-induced oxidative stress in streptozotocin-induced diabetic rats”, Journal of Trace Elements in Medicine and Biology 27(2). 117-121. 2013.
 
[19]  F.M. Refaie, A.Y. Esmat, A.F. Mohamed, W.H.A. Nour, “Effect of chromium supplementation on the diabetes induced-oxidative stress in liver and brain of adult rats”, Biometals 22(6). 1075-1087. Dec.2009.
 
[20]  K. Sahin, M. Tuzcu, C. Orhan, N. Sahin, O. Kucuk, I.H. Ozercan, V. Juturu, J.R. Komorowski, “Anti-diabetic activity of chromium picolinate and biotin in rats with type 2 diabetes induced by high-fat diet and streptozotocin”, British Journal of Nutrition 110(2). 197-205. Jul.2013.
 
[21]  A.A. Seif, “Chromium picolinate inhibits cholesterol-induced stimulation of platelet aggregation in hypercholesterolemic rats”, Irish Journal of Medical Science 184(2). 291-296. Jun.2015.
 
[22]  M.J. Gonzalez Munoz, I. Meseguer, M.C. Martinez Para, M.V. Aguilar, A. Bernao, “Repercussions of chromium picolinate in the protein metabolism based on the age”, Nutricion Hospitalaria 21(6). 709-714. Nov.2006.
 
[23]  M. Vrtovec, B. Vrtovec, A. Briski, A. Kocijancic, R.A. Anderson, B. Radovancevic, “Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus”, American Heart Journal 149(4). 632-636. Apr.2005.
 
[24]  G.L. Chen, P. Liu, G. Pattar, L. Tackett, P. Bhonagiri, A.B. Strawbridge, J.S. Elmendorf, “Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism”, Molecular Endocrinology 20(4). 857-870. Apr.2006.
 
[25]  N. Sreejayan, F. Dong, M.R. Kandadi, X. Yang, J. Ren, “Chromium alleviates glucose intolerance, insulin resistance, and hepatic ER stress in obese mice”, Obesity 16(6). 1331-1337. Jun.2008.
 
[26]  E.M. Horvath, L. Tackett, A.M. McCarthy, P. Raman, J.T. Brozinick, J.S. Elmendorf, “Antidiabetogenic effects of chromium mitigate Hyperinsulinemia-induced cellular insulin resistance via correction of plasma membrane cholesterol imbalance” (Retracted article. See vol. 24, pg. 1308, 2010), Molecular Endocrinology 22(4). 937-950. Apr. 2008.
 
[27]  W.T. Cefalu, Z.Q. Wang, X.H. Zhang, L.C. Baldor, J.C. Russell, “Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats”, Journal of Nutrition 132(6). 1107-1114. Jun.2002.
 
[28]  K.A. Brownley, C.A. Boettiger, L. Young, W.T. Cefalu, “Dietary chromium supplementation for targeted treatment of diabetes patients with comorbid depression and binge eating”, Medical Hypotheses 85(1). 45-48. Jul.2015.
 
[29]  D.C. Jimerson, M.D. Lesem, W.H. Kaye, T.D. Brewerton, “Low seratonin and dopamine metabolite concentrations in cerebrospinal-fluid from bulimic patients with frequence binge episodes”, Archives of General Psychiatry 49(2). 132-138. Feb.1992.
 
[30]  T. Reichborn-Kjennerud, C.M. Bulik, P.F. Sullivan, K. Tambs, J.R. Harris, “Psychiatric and medical symptoms in binge eating in the absence of compensatory behaviors”, Obesity Research 12(9). 1445-1454. Sep.2004.
 
[31]  R. Krikorian, J.C. Eliassen, E.L. Boespflug, T.A. Nash, M.D. Shidler, “Improved cognitive-cerebral function in older adults with chromium supplementation”, Nutritional Neuroscience 13(3). 116-122. Jun.2010.
 
[32]  L.D. Baker, B. Cholerton, M. Reger, S. Watson, D. Chapman, K. Enstrom, K. Hyde, S. Craft, “Hyperinsulinemia predicts cognitive performance for normal older adults and for patients with Alzheimer's disease”, Neurobiology of Aging 25. 110-110. Jul.2004.
 
[33]  S. Craft, “Insulin resistance syndrome and Alzheimer's disease: Age- and obesity-related effects on memory, amyloid, and inflammation”, Neurobiology of Aging 26. 65-69. Dec.2005.
 
[34]  U. Masharani, C. Gjerde, S. McCoy, B.A. Maddux, D. Hessler, I.D. Goldfine, J.F. Youngren, “Chromium supplementation in non-obese non-diabetic subjects is associated with a decline in insulin sensitivity”, Bmc Endocrine Disorders 12. Nov.2012.
 
[35]  A. Ali, Y. Ma, J. Reynolds, J.P. Wise, Sr., S.E. Inzucchi, D.L. Katz, “Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus”, Endocrine Practice 17(1). 16-25. Jan.2011.
 
[36]  N. Iqbal, S. Cardillo, S. Volger, L.T. Bloedon, R.A. Anderson, R. Boston, P.O. Szapary, “Chromium picolinate does not improve key features of metabolic syndrome in obese nondiabetic adults”, Metab Syndr Relat Disord 7(2). 143-50. Apr.2009.
 
[37]  R.A. Anderson, N.Z. Cheng, N.A. Bryden, M.M. Polansky, N.P. Cheng, J.M. Chi, J.G. Feng, “Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes”, Diabetes 46(11). 1786-1791. Nov.1997.
 
[38]  N. Kleefstra, R.O.B. Gans, S.T. Houweling, B. Meyboom-de Jong, S.J.L. Bakker, H.J.G. Bilo, S. Verhoeven, “Chromium treatment has no effect in patients with type 2 diabetes in a western population - A randomized, double-blind, placebo-controlled trial”, Diabetes Care 30(5). 1092-1096. May.2007.
 
[39]  K.T. Weber, W.B. Weglicki, R.U. Simpson, “Macro- and micronutrient dyshomeostasis in the adverse structural remodelling of myocardium”, Cardiovascular Research 81(3). 500-508. Feb.2009.
 
[40]  Z.Q. Wang, J. Qin, J. Martin, X.H. Zhang, O. Sereda, R.A. Anderson, P. Pinsonat, W.T. Cefalu, “Phenotype of subjects with type 2 diabetes mellitus may determine clinical response to chromium supplementation”, Metabolism-Clinical and Experimental 56(12). 1652-1655. Dec.2007.
 
[41]  C.H. Bailey, “Improved meta-analytic methods show no effect of chromium supplements on fasting glucose”, Biol Trace Elem Res 157(1). 1-8. Jan.2014.
 
[42]  R.B. Costello, J.T. Dwyer, R.L. Bailey, “Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness Nutrition Reviews”, 0(0). 1-14. 2016.
 
[43]  G.W. Landman, H.J. Bilo, S.T. Houweling, N. Kleefstra, “Chromium does not belong in the diabetes treatment arsenal: Current evidence and future perspectives”, World J Diabetes 5(2). 160-4. Apr.2014.
 
[44]  N. Wiernsperger, J. Rapin, “Trace elements in glucometabolic disorders: an update”, Diabetology & Metabolic Syndrome 2. Dec.2010.
 
[45]  E.M. Balk, A. Tatsioni, A.H. Lichtenstein, J. Lau, A.G. Pittas, “Effect of chromium supplementation on glucose metabolism and lipids - A systematic review of randomized controlled trials”, Diabetes Care 30(8). 2154-2163. Aug.2007.
 
[46]  J.J. Otten, J.P. Hellwig, L.D. Meyers, “Dietary Reference Intakes: The Essential Guide to Nutrient Requirements”, National Academy of Sciences, The National Academies Press, 2006.
 
[47]  S.Y. Chen, T.F. Lien, “Toxicity evaluation of chromium picolinate nanoparticles in vivo and in vitro in rat” Biol Trace Elem Res 151(2). 247-255. Feb. 2013.
 
[48]  B. Sundaram, K. Singhal, R. Sandhir, “Anti-atherogenic effect of chromium picolinate in streptozotocin-induced experimental diabetes”, Journal of Diabetes 5(1). 43-50. Mar.2013.